ES2507515T3 - Formulación que comprende mutante(s) de alfa-Galactosidasa A lisosomal para el tratamiento de enfermedad de Fabry - Google Patents
Formulación que comprende mutante(s) de alfa-Galactosidasa A lisosomal para el tratamiento de enfermedad de Fabry Download PDFInfo
- Publication number
- ES2507515T3 ES2507515T3 ES09011761.5T ES09011761T ES2507515T3 ES 2507515 T3 ES2507515 T3 ES 2507515T3 ES 09011761 T ES09011761 T ES 09011761T ES 2507515 T3 ES2507515 T3 ES 2507515T3
- Authority
- ES
- Spain
- Prior art keywords
- gal
- dgj
- fabry
- mutant
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/087,804 US6274597B1 (en) | 1998-06-01 | 1998-06-01 | Method of enhancing lysosomal α-Galactosidase A |
US87804 | 1998-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2507515T3 true ES2507515T3 (es) | 2014-10-15 |
Family
ID=22207362
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES99925611T Expired - Lifetime ES2333561T3 (es) | 1998-06-01 | 1999-05-28 | Derivados de 1-desoxi-galactonojirimicina y su uso en el tratamiento de enfermadades relacionadas con el almacenamiento lisosomal potenciando la alfa-galactosidasa a lisosomal. |
ES09011761.5T Expired - Lifetime ES2507515T3 (es) | 1998-06-01 | 1999-05-28 | Formulación que comprende mutante(s) de alfa-Galactosidasa A lisosomal para el tratamiento de enfermedad de Fabry |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES99925611T Expired - Lifetime ES2333561T3 (es) | 1998-06-01 | 1999-05-28 | Derivados de 1-desoxi-galactonojirimicina y su uso en el tratamiento de enfermadades relacionadas con el almacenamiento lisosomal potenciando la alfa-galactosidasa a lisosomal. |
Country Status (12)
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
US20050032841A1 (en) * | 1999-04-20 | 2005-02-10 | Steven Walkley | Therapeutic compositions and methods of treating glycolipid storage related disorders |
JP2003523330A (ja) | 2000-02-04 | 2003-08-05 | チルドレンズ・ホスピタル・リサーチ・ファウンデイション | アテローム性動脈硬化症および関連疾患のための脂質加水分解治療 |
CA2459887C (en) * | 2001-09-07 | 2011-08-09 | Seikagaku Corporation | Carba-sugar amine derivative and glycolipid metabolic disorder treating agent containing the same as active ingredient |
US7842470B2 (en) * | 2001-10-09 | 2010-11-30 | Oregon Health & Science University | Method for pharmacoperones correction of GnRHR mutant protein misfolding |
WO2004004740A1 (en) * | 2002-07-05 | 2004-01-15 | King Roderick Frederick Gerard | Aqueous formulation comprising digestible saccharides to reduce the tendency to cardiovascular disease in a subject |
AU2003284886A1 (en) * | 2002-10-21 | 2004-05-13 | William E. Balch | CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF Beta-GLUCOSIDASE |
ES2686775T3 (es) | 2003-01-31 | 2018-10-19 | Mount Sinai School Of Medicine Of New York University | Terapia de combinación para tratar trastornos de deficiencia de proteínas |
US7446098B2 (en) * | 2003-02-18 | 2008-11-04 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiencies |
EP1633356A1 (en) * | 2003-05-22 | 2006-03-15 | The Hospital for Sick Children | Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity |
FR2861991B1 (fr) | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
EP1682504B1 (en) * | 2003-11-12 | 2012-12-26 | Amicus Therapeutics Inc. | Hydroxy piperidine derivatives to treat gaucher disease |
US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
CA2507348C (en) * | 2004-05-13 | 2013-07-16 | The Hospital For Sick Children | Real time methylumbelliferone-based assay |
WO2005115429A1 (en) * | 2004-05-24 | 2005-12-08 | Ramot At Tel Aviv University Ltd. | Methods and kits for diagnosing and/or assessing severity and treating gaucher disease |
JP2008503590A (ja) * | 2004-06-21 | 2008-02-07 | メドトロニック・インコーポレーテッド | 組成物を細胞にデリバリーするための医学用システム及び方法 |
US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
FR2873377B1 (fr) * | 2004-07-23 | 2006-10-13 | Sanofi Synthelabo | Derives d'azasucre, inhibiteurs d'heparanases, leur procede de preparation, les compositions en contenant et leur utilisation |
EP3441090A1 (en) * | 2005-05-17 | 2019-02-13 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
EP1888068B1 (en) * | 2005-06-08 | 2014-05-21 | Amicus Therapeutics, Inc. | Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes |
FR2887549B1 (fr) * | 2005-06-23 | 2009-07-10 | Centre Nat Rech Scient | Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation |
WO2007030375A2 (en) * | 2005-09-08 | 2007-03-15 | Children's Hospital Medical Center | Lysosomal acid lipase therapy for nafld and related diseases |
AU2013205532B8 (en) * | 2006-05-16 | 2015-07-16 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for fabry disease |
DK2533050T6 (da) * | 2006-05-16 | 2015-09-21 | Amicus Therapeutics Inc | Behandlingsmuligheder ved Fabrys sygdom |
AU2015230773B2 (en) * | 2006-05-16 | 2017-09-28 | Amicus Therapeutics Inc. | Assays for diagnosing and evaluating treatment options for fabry disease |
US7501439B2 (en) * | 2006-05-24 | 2009-03-10 | Amicus Therapeutics, Inc. | Tartrate salt of isofagomine and methods of use |
ES2364586T3 (es) * | 2006-05-24 | 2011-09-07 | Amicus Therapeutics, Inc. | Sal tartrato de isofagomina y métodos de uso. |
JP5303458B2 (ja) | 2006-06-23 | 2013-10-02 | アミークス セラピューティックス インコーポレイテッド | β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法 |
US20080138351A1 (en) * | 2006-08-02 | 2008-06-12 | United Therapeutics Corporation | Liposome treatment of viral infections |
EP2121005A1 (en) * | 2006-12-21 | 2009-11-25 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Treatment of fabry disease |
EP2155197A4 (en) * | 2007-03-09 | 2011-10-12 | Link Medicine Corp | TREATMENT OF LYSOSOMAL STORAGE DISEASES |
CA2682441A1 (en) * | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of fabry disease using pharmacological chaperones |
MX2009011055A (es) * | 2007-04-13 | 2010-01-13 | Amicus Therapeutics Inc | Tratamiento de la enfermedad de gaucher con chaperonas farmacologicas especificas y supervision del tratamiento utilizando marcadores sustitutos. |
JP2010523160A (ja) * | 2007-04-13 | 2010-07-15 | アミカス セラピューティックス インコーポレイテッド | 薬理学的シャペロンとしての基質の使用 |
EP2150254A4 (en) * | 2007-04-26 | 2010-11-10 | Amicus Therapeutics Inc | DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES |
US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
EP2152265B1 (en) | 2007-05-22 | 2014-06-04 | Amicus Therapeutics, Inc. | New method for preparing isofagomine and its derivatives |
WO2009049421A1 (en) * | 2007-10-18 | 2009-04-23 | The Hospital For Sick Children | Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease |
WO2009066069A1 (en) * | 2007-11-21 | 2009-05-28 | Summit Corporation Plc | Treatment of protein folding disorders |
HUE051377T2 (hu) * | 2008-02-12 | 2021-03-01 | Amicus Therapeutics Inc | Eljárás betegségek gyógyászati chaperonnal történõ kezelésére adott válasz elõrejelzésére |
JP2011518124A (ja) * | 2008-03-26 | 2011-06-23 | ユニバーシティ・オブ・オックスフォード | 小胞体ターゲッティングリポソーム |
CA2728363C (en) | 2008-06-26 | 2019-02-19 | Orphazyme Aps | Use of hsp70 as a regulator of enzymatic activity |
US8321148B2 (en) * | 2008-10-24 | 2012-11-27 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
US20100119502A1 (en) * | 2008-11-11 | 2010-05-13 | Amicus Therapeutics, Inc. | Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease |
KR20120059447A (ko) * | 2009-03-27 | 2012-06-08 | 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 | 콜레스테롤 수준 저하 리포좀 |
GB0906159D0 (en) * | 2009-04-09 | 2009-05-20 | Summit Corp Plc | Drug combination for the treatment of proteostatic diseases |
US9206457B2 (en) * | 2009-05-26 | 2015-12-08 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
US20110070643A1 (en) * | 2009-05-26 | 2011-03-24 | Do Hung V | Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics |
TW201117810A (en) * | 2009-10-01 | 2011-06-01 | Baylor Res Inst | Treatment of male-pattern baldness by local induction of the metabolic defect of fabry disease |
BR112012009123A2 (pt) * | 2009-10-19 | 2017-09-19 | Amicus Therapeutics Inc | novas composições para a prevenção e/ou tratamento de distúrbios de depósito lisossômico |
DK2490712T3 (en) | 2009-10-19 | 2015-10-05 | Amicus Therapeutics Inc | PROCESS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BY USING Pharmacological chaperones TO INCREASE ACTIVITY OF GANGLIOSIDASER |
ES2617192T3 (es) * | 2009-10-19 | 2017-06-15 | Amicus Therapeutics, Inc. | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central |
US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
ES2555555T3 (es) * | 2010-01-28 | 2016-01-04 | Raptor Pharmaceuticals Inc. | Conjugados de péptido de proteína asociada al receptor inhibidor de fucosidasa y su uso en el tratamiento de tumores hepáticos |
CN102985092A (zh) * | 2010-02-02 | 2013-03-20 | 牛津大学之校长及学者 | 从D-葡糖醛酸内酯合成DGJNAc以及用来抑制α-N-乙酰半乳糖胺酶的用途 |
AU2011335545A1 (en) | 2010-11-30 | 2013-06-13 | Orphazyme Aps | Methods for increasing intracellular activity of Hsp70 |
SG193379A1 (en) * | 2011-03-11 | 2013-10-30 | Amicus Therapeutics Inc | Dosing regimens for the treatment of fabry disease |
LT2753346T (lt) | 2011-09-07 | 2020-08-10 | Mount Sinai School Of Medicine | Ceramidazė ir ląstelių diferenciacija |
EP2785335B8 (en) | 2011-11-29 | 2017-08-02 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for the treatment of darier disease |
WO2013134530A1 (en) | 2012-03-07 | 2013-09-12 | Amicus Therapeutics, Inc. | High concentration alpha-glucosidase compositions for the treatment of pompe disease |
ES2897825T3 (es) | 2012-06-01 | 2022-03-02 | Icahn School Med Mount Sinai | Niveles de ceramida en el tratamiento y prevención de infecciones |
CN104918619B (zh) | 2013-01-09 | 2019-04-02 | 阿米库斯治疗学公司 | 稳定的肠胃外dnj组合物 |
EP2968479B1 (en) | 2013-03-14 | 2019-07-17 | Icahn School of Medicine at Mount Sinai | Therapeutic acid ceramidase compositions and methods of making and using them |
US9675627B2 (en) | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
PT3193840T (pt) | 2014-09-15 | 2021-08-10 | Orphazyme Aps | Formulação de arimoclomol |
BR112017005810A2 (pt) | 2014-09-30 | 2018-02-27 | Amicus Therapeutics Inc | alfa-glucosidase ácida altamente potente com carboidratos melhorados |
CA2973940C (en) | 2015-02-05 | 2022-08-23 | Mitraltech Ltd. | Prosthetic valve with axially-sliding frames |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
KR102510941B1 (ko) | 2015-12-30 | 2023-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
EP3432882B1 (en) * | 2016-03-22 | 2021-09-01 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having the g9331a mutation in the gla gene |
SG11201808455VA (en) | 2016-03-30 | 2018-10-30 | Amicus Therapeutics Inc | Formulations comprising recombinant acid alpha-glucosidase |
BR112018070189A2 (pt) | 2016-03-30 | 2019-02-19 | Amicus Therapeutics, Inc. | método para seleção de proteínas recombinantes ricas em m6p |
EP3442530A1 (en) | 2016-04-13 | 2019-02-20 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
KR102254140B1 (ko) | 2016-04-29 | 2021-05-24 | 오르파짐 에이/에스 | 글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰 |
US20190183869A1 (en) | 2016-07-19 | 2019-06-20 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naïve and ert-experienced patients |
NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
EP4324522A2 (en) | 2017-05-30 | 2024-02-21 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
KR102631805B1 (ko) | 2017-05-30 | 2024-01-31 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 신장 손상을 갖는 파브리 환자를 치료하는 방법 |
US11306058B2 (en) | 2017-06-01 | 2022-04-19 | Idorsia Pharmaceuticals Ltd | Crystalline form of N-butyldeoxygalactonojirimycin |
JP7066157B2 (ja) * | 2017-06-14 | 2022-05-13 | 学校法人 明治薬科大学 | ファブリー病治療用医薬の組合せ物及びその利用 |
SG11202000423XA (en) | 2017-07-19 | 2020-02-27 | Amicus Therapeutics Inc | Treatment of fabry disease in ert-naïve and ert-experienced patients |
US11819405B2 (en) | 2017-09-19 | 2023-11-21 | Cardiovalve Ltd. | Prosthetic valve with inflatable cuff configured for radial extension |
KR20200044908A (ko) | 2017-08-28 | 2020-04-29 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법 |
JP7252211B2 (ja) * | 2017-09-08 | 2023-04-04 | ザ ヌムール ファウンデーション | リソソーム蓄積症を治療するための薬剤、デバイス、および血液循環システム、ならびにリソソーム蓄積症を治療するための方法 |
CN107699590A (zh) * | 2017-10-13 | 2018-02-16 | 成都中医药大学 | 一种制备重组人α‑L‑艾杜糖醛酸酶的方法 |
ES2716305B2 (es) | 2017-12-11 | 2019-11-27 | Fund Biomedica Galicia Sur | Uso de chaperonas farmacologicas para el tratamiento de enfermedades de deposito lisosomal |
KR20200128676A (ko) | 2018-02-06 | 2020-11-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도 |
PL3749308T3 (pl) | 2018-02-06 | 2024-03-25 | Amicus Therapeutics, Inc. | Leczenie pacjentów z klasyczną chorobą fabry’ego migalastatem |
US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
US20210315875A1 (en) | 2018-08-20 | 2021-10-14 | Amicus Therapeutics, Inc. | Methods of Treating Fabry Disease in Patients Having a Mutation in the GLA Gene |
TW202042812A (zh) | 2019-01-22 | 2020-12-01 | 美商阿米庫斯醫療股份有限公司 | 減少法布瑞氏症患者中之腦血管事件之方法 |
CA3141226A1 (en) | 2019-06-11 | 2020-12-17 | Franklin Johnson | Methods of treating fabry disease in patients having renal impairment |
US11833164B2 (en) | 2019-08-07 | 2023-12-05 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
JP2022548162A (ja) * | 2019-10-04 | 2022-11-16 | アカデミア シニカ | ポンペ病を処置する方法 |
MX2022006366A (es) * | 2019-11-27 | 2022-06-22 | Turning Point Therapeutics Inc | Terapia de combinacion que implica compuestos de diarilo macrociclico. |
AU2021218578A1 (en) * | 2020-02-10 | 2022-08-25 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease |
CA3170718A1 (en) | 2020-03-06 | 2021-09-10 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having a mutation in the gla gene |
EP4247792A1 (en) | 2020-11-19 | 2023-09-27 | Zevra Denmark A/S | Processes for preparing arimoclomol citrate and intermediates thereof |
US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
CA3225511A1 (en) | 2021-07-12 | 2023-01-19 | Franklin Johnson | Methods of treating fabry disease in pediatric patients |
WO2023060233A1 (en) | 2021-10-08 | 2023-04-13 | Amicus Therapeutics, Inc. | Biomarkers for lysosomal storage diseases |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
JPS61280472A (ja) | 1985-06-05 | 1986-12-11 | Shionogi & Co Ltd | β−ガラクトシダ−ゼ阻害物質ガラクトスタチン類およびその製造方法 |
DE3650377T2 (de) | 1985-12-23 | 1996-02-22 | Hutchinson Fred Cancer Res | Regulierung der retroviralen replikation, infektion und pathogenese. |
DE3737523A1 (de) | 1987-11-05 | 1989-05-18 | Bayer Ag | Verwendung von substituierten hydroxypiperidinen als antivirale mittel |
US5192772A (en) | 1987-12-09 | 1993-03-09 | Nippon Shinyaku Co. Ltd. | Therapeutic agents |
US5250545A (en) | 1988-02-12 | 1993-10-05 | Meiji Seika Kaisha, Ltd. | Cancer cell metastasis inhibitor methods |
FR2640621B1 (fr) | 1988-12-19 | 1992-10-30 | Centre Nat Rech Scient | N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases |
US5043273A (en) | 1989-08-17 | 1991-08-27 | Monsanto Company | Phosphorylated glycosidase inhibitor prodrugs |
US5030638A (en) * | 1990-02-26 | 1991-07-09 | G. D. Searle & Co. | Method of antiviral enhancement |
US5504078A (en) | 1990-06-08 | 1996-04-02 | Merrell Dow Pharmaceuticals Inc. | α-glucosidase inhibitors |
WO1992000277A1 (fr) | 1990-06-29 | 1992-01-09 | Nippon Shinyaku Co., Ltd. | Derive de piperidine |
US5276120A (en) | 1991-05-30 | 1994-01-04 | The Scripps Research Institute | Process for forming omega-deuxy-azasugars |
US6291657B1 (en) | 1993-05-13 | 2001-09-18 | Monsanto Company | Deoxygalactonojirimycin derivatives |
US5798366A (en) | 1993-05-13 | 1998-08-25 | Monsanto Company | Method for treatment of CNS-involved lysosomal storage diseases |
US5399567A (en) * | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
JPH0748398A (ja) | 1993-08-03 | 1995-02-21 | Nippon Oil Co Ltd | 変性蛋白質の再生方法及び変性蛋白質再生剤 |
US5691306A (en) | 1993-08-26 | 1997-11-25 | National Research Council Of Canada | Methods of detection and treatment of protein trafficking disorders and increasing secretory protein production |
US6037351A (en) | 1994-01-13 | 2000-03-14 | G. D. Searle & Co. | Method of inhibiting hepatitis B virus |
WO1995022975A1 (en) | 1994-02-25 | 1995-08-31 | G.D. Searle & Co. | Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus |
US5863903A (en) | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
US5844102A (en) | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
AU732552B2 (en) | 1996-07-15 | 2001-04-26 | Genzyme Corporation | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
EP1538202B1 (en) | 1996-09-13 | 2014-01-22 | Shire Human Genetic Therapies, Inc. | Production of human alpha-galactosidase A |
GB9700233D0 (en) | 1997-01-08 | 1997-02-26 | Univ London | Use of glycosidase inhibitors |
US6210666B1 (en) * | 1997-10-21 | 2001-04-03 | Orphan Medical, Inc. | Truncated α-galactosidase A to treat fabry disease |
AU753336B2 (en) | 1997-11-10 | 2002-10-17 | G.D. Searle & Co. | Use of alkylated iminosugars to treat multidrug resistance |
US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
AU2590099A (en) | 1998-02-09 | 1999-08-23 | William J. Netzer | Protein folding inhibitors |
US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
AU1734600A (en) | 1998-11-17 | 2000-06-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Identification of glycosphingolipids that promote hiv-1 entry into cells |
WO2000032175A2 (en) | 1998-12-02 | 2000-06-08 | Pfizer Products Inc. | METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY |
US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
JP2000219632A (ja) | 1999-01-28 | 2000-08-08 | Toyotama Koryo Kk | カロリー軽減剤 |
WO2000056334A1 (en) | 1999-03-19 | 2000-09-28 | The Trustees Of Boston College | Use of imino sugars for anti-tumor therapy |
CN1355708A (zh) | 1999-04-19 | 2002-06-26 | 先灵公司 | 包含利巴韦林与抗氧化剂的hcv联合治疗 |
GB9909064D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
US6476194B1 (en) | 1999-06-29 | 2002-11-05 | National Research Council Of Canada | Method for folding unfolded proteins |
WO2001007078A1 (en) | 1999-07-26 | 2001-02-01 | G.D. Searle & Co. | Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases |
AU1840101A (en) | 1999-08-10 | 2001-03-05 | Chancellor, Masters And Scholars Of The University Of Oxford, The | Long chain n-alkyl compounds and oxo-derivatives thereof |
AU7712000A (en) | 1999-09-24 | 2001-04-24 | Johns Hopkins University School Of Medicine, The | Methods for identifying an agent that corrects defective protein folding |
US6656912B2 (en) | 2000-01-20 | 2003-12-02 | Washington University In St. Louis | Methods to treat α1-antitrypsin deficiency |
AU2001269923A1 (en) | 2000-06-19 | 2002-01-02 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
AU2002211379A1 (en) | 2000-10-04 | 2002-04-15 | The Children's Hospital Of Philadelphia | Compositions and methods for treatment of cystic fibrosis |
JP2002190202A (ja) | 2000-10-12 | 2002-07-05 | Koito Mfg Co Ltd | ヘッドランプ |
JP3589449B2 (ja) | 2001-02-26 | 2004-11-17 | 株式会社ユニレック | 静電容量センサ、管内流動判断装置、管内流動制御装置 |
JP4802548B2 (ja) * | 2005-04-28 | 2011-10-26 | シンフォニアテクノロジー株式会社 | Icチップ実装体の製造装置 |
US7174582B1 (en) | 2005-08-17 | 2007-02-13 | Kevin J Leary | Crib mattress bouncer |
US20110053901A1 (en) | 2008-02-14 | 2011-03-03 | Signum Biosciences, Inc. | Acetyl mimic compounds for the inhibition of isoprenyl-s-cysteinyl methyltransferase |
EP3330252B1 (en) | 2008-11-11 | 2020-02-12 | Signum Biosciences, Inc. | Isoprenyl compounds and methods thereof |
EP2389357A4 (en) | 2009-01-20 | 2013-01-23 | Signum Biosciences Inc | INFLAMMATORY COMPLEXES |
-
1998
- 1998-06-01 US US09/087,804 patent/US6274597B1/en not_active Expired - Lifetime
-
1999
- 1999-05-28 DK DK99925611.8T patent/DK1083899T3/da active
- 1999-05-28 EP EP99925611A patent/EP1083899B1/en not_active Expired - Lifetime
- 1999-05-28 ES ES99925611T patent/ES2333561T3/es not_active Expired - Lifetime
- 1999-05-28 EP EP09011761.5A patent/EP2143420B1/en not_active Expired - Lifetime
- 1999-05-28 DK DK09011761.5T patent/DK2143420T3/da active
- 1999-05-28 WO PCT/US1999/010479 patent/WO1999062517A1/en active Application Filing
- 1999-05-28 AU AU41861/99A patent/AU4186199A/en not_active Abandoned
- 1999-05-28 JP JP2000551773A patent/JP4602548B2/ja not_active Expired - Lifetime
- 1999-05-28 DE DE69941429T patent/DE69941429D1/de not_active Expired - Lifetime
- 1999-05-28 PT PT90117615T patent/PT2143420E/pt unknown
- 1999-05-28 PT PT99925611T patent/PT1083899E/pt unknown
- 1999-05-28 AT AT99925611T patent/ATE442851T1/de active
- 1999-05-28 CA CA2333965A patent/CA2333965C/en not_active Expired - Lifetime
- 1999-05-28 ES ES09011761.5T patent/ES2507515T3/es not_active Expired - Lifetime
-
2000
- 2000-06-26 US US09/604,053 patent/US6583158B1/en not_active Expired - Lifetime
-
2001
- 2001-08-10 US US09/927,285 patent/US6774135B2/en not_active Expired - Lifetime
- 2001-09-07 US US09/948,348 patent/US6599919B2/en not_active Expired - Lifetime
-
2002
- 2002-06-14 US US10/172,604 patent/US6589964B2/en not_active Expired - Lifetime
- 2002-11-26 US US10/304,395 patent/US6916829B2/en not_active Expired - Lifetime
-
2004
- 2004-06-14 US US10/868,133 patent/US7622485B2/en not_active Expired - Fee Related
- 2004-11-16 US US10/989,258 patent/US7141582B2/en not_active Expired - Lifetime
-
2005
- 2005-10-31 US US11/264,672 patent/US7514453B2/en not_active Expired - Fee Related
-
2006
- 2006-09-27 US US11/528,903 patent/US7812033B2/en not_active Expired - Fee Related
-
2009
- 2009-11-23 US US12/624,026 patent/US8633221B2/en not_active Expired - Fee Related
- 2009-12-16 CY CY20091101305T patent/CY1112845T1/el unknown
-
2010
- 2010-08-02 JP JP2010173733A patent/JP5528941B2/ja not_active Expired - Lifetime
- 2010-09-24 US US12/890,014 patent/US8436018B2/en not_active Expired - Fee Related
-
2013
- 2013-04-22 US US13/867,914 patent/US8841322B2/en not_active Expired - Fee Related
- 2013-12-20 US US14/136,418 patent/US9265780B2/en not_active Expired - Fee Related
-
2014
- 2014-08-18 US US14/461,827 patent/US20150258129A1/en not_active Abandoned
- 2014-09-24 CY CY20141100776T patent/CY1115583T1/el unknown
-
2016
- 2016-01-25 US US15/005,371 patent/US20160346262A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2507515T3 (es) | Formulación que comprende mutante(s) de alfa-Galactosidasa A lisosomal para el tratamiento de enfermedad de Fabry | |
ES2200865T3 (es) | Combinacion de n-butildesoxino,jirimicina (nb-onj) y enzimas degradadoras de glicolipidos en terapia. | |
Paradies et al. | Cardiolipin and mitochondrial function in health and disease | |
CN110201144B (zh) | 用Nutlin-3a和肽抑制肺纤维化 | |
HU227935B1 (en) | Use of strontium salts for the production of pharmaceutical compositions intended for the treatment of arthrosis | |
US7858085B2 (en) | Alkaline phosphatase to control diabetes | |
Von Figura et al. | Juvenile and adult metachromatic leukodystrophy: partial restoration of arylsulfatase A (cerebroside sulfatase) activity by inhibitors of thiol proteinases. | |
Seker Yilmaz et al. | Novel therapies for mucopolysaccharidosis type III | |
JP2009538276A (ja) | 嚢胞性線維症の改良型治療 | |
KR20140107481A (ko) | 리소좀 효소를 재배열하는 능력을 갖는 화합물 및 암브록솔 및/또는 암브록솔의 유도체의 조합물 | |
ES2751391T3 (es) | Procedimientos de tratamiento de trastornos metabólicos | |
JP2010533657A (ja) | アミロイドタンパク質に関係する疾患を治療するための組織カリクレイン | |
Versluis et al. | Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes | |
US20240075113A1 (en) | Compositions and methods for treating farber disease | |
Lei et al. | Enzyme enhancement activity of N-octyl-β-valienamine on β-glucosidase mutants associated with Gaucher disease | |
Matassini et al. | Carbohydrate‐Based Therapeutics for Lysosomal Storage Disorders | |
US20240000768A1 (en) | Method for the treatment of diseases associated with sulfatase deficiencies | |
ES2472115B1 (es) | Utilización de derivados bicíclicos de 1-desoxigalactonojirimicina en la preparación de un medicamento para el tratamiento de enfermedades relacionadas con beta-enzimas galactosidasas lisosómicas mutantes humanas | |
WO2024036044A1 (en) | Compositions and methods for treating and preventing metabolic disorders | |
EA029370B1 (ru) | Применение одипарцила в лечении мукополисахаридоза | |
BR112012004651A2 (pt) | surfactante pulmonar exógeno, uso de uma combinação terapêutica, medicamento e kit | |
Cowell et al. | Structural and Functional Aspects of the Intestinal Brush Border |